Ocular manifestations in the mucopolysaccharidoses - a review

Clinical and Experimental Ophthalmology

Volumn 38, Issue SUPPL. 1, 2010, Pages 12-22

  Ashworth, Jane L ^a   Kruse, Friedrich E ^b   Bachmann, Björn ^b   Tormene, Alma P ^c   Suppiej, Agnese ^d   Parini, Rossella ^e   Guffon, Nathalie ^f  

^a MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f HOSPICES CIVILS DE LYON   (France)

Author keywords

Diagnosis; Eye disease; Glycosaminoglycan; Mucopolysaccharidosis

Indexed keywords

GLYCOSAMINOGLYCAN;

CHILD; CONJUNCTIVA; COOPERATION; CORNEA; CORNEA VASCULARIZATION; DISEASE COURSE; ELECTRORETINOGRAPHY; ENZYME ACTIVITY; EYE EDEMA; EYE MOVEMENT; FOLLOW UP; GLAUCOMA; HUMAN; INTRACRANIAL PRESSURE; INTRAOCULAR PRESSURE; MUCOPOLYSACCHARIDOSIS; OPHTHALMOSCOPY; OPTIC DISK; OPTIC NERVE ATROPHY; PHOTOPHOBIA; PREVALENCE; REFRACTION ERROR; RETINA MACULA DEGENERATION; RETINOPATHY; REVIEW; SLIT LAMP; VISION; VISUAL ACUITY;

EID: 77955399242     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2010.02364.x     Document Type: Review

References (48)

1. Baehner F, Schmiedeskamp C, Krummenauer F. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005, 28:1011-17.
2. Lin HY, Lin SP, Chuang CK. Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A 2009, 149A:960-4.
3. Neufeld EF, Muenzer J. The mucopolysaccharidoses. The Metabolic and Molecular Bases of Inherited Disease 2001, 3421-52. Scriver CR, Beaudet ALSly WSValle D. In, eds., 8th, edn. Chapt 136, New York, McGraw-Hill Medical Publishing Division
4. Kerryson JB. Sction X Degenerative and metabolic diseases. Walsh & Hoyt's Clinical Neuro-Ophthalmology 2005, 2469-550. Miller NRNewman NJ. In, eds., Philadelphia, PA, Lippincott Williams & Wilkins
5. Roy FH, Fraunfelder FW, Fraunfelder FT. Section 5 Disorders of carbohydrate metabolism. Roy and Fraunfelder's Current Ocular Therapy 127-41. eds, 6th, edn., Saunders Elsevier, Philadelphia, USA
6. Willoughby CE, Ponzin D, Ferrari S. Anatomy and physiology of the human eye: effects of mucopolysaccharidosis disease on structure and function. Clin Experiment Ophthalmol 2010, 38(S1):2-11.
7. Kenyon KR. Ocular manifestations and pathology of systemic mucopolysaccharidoses. Birth Defects Orig Artic Ser 1976, 12:133-53.
8. Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidoses and the eye. Surv Ophthalmol 2006, 51:1-17.
9. Ferrari S, Ponzin D, Ashworth JL. Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis. Br J Ophthalmol 2010, doi:10.1136/bjo.2010.179937
10. Ashworth JL, Biswas S, Wraith E, Lloyd IC. The ocular features of the mucopolysaccharidoses. Eye 2006, 20:553-63.
11. Abraham FA, Yatziv S, Russell A, Auerbach E. Electrophysiological and psychophysical findings in Hunter syndrome. Arch Ophthalmol 1974, 91:181-6.
12. Käsmann-Kellner B, Weindler J, Pfau B, Ruprecht KW. Ocular changes in mucopolysaccharidosis IV A (Morquio A syndrome) and long-term results of perforating keratoplasty. Ophthalmologica 1999, 213:200-5.
13. Connell P, McCreery K, Doyle A, Darcy F, O'Meara A, Brosnahan D. Central corneal thickness and its relationship to intraocular pressure in mucopolysaccararidoses-1 following bone marrow transplantation. J AAPOS 2008, 12:7-10.
14. Fahnehjelm KT, Törnquist AL, Malm G, Winiarski J. Ocular findings in four children with mucopolysaccharidosis I-Hurler (MPS I-H) treated early with haematopoietic stem cell transplantation. Acta Ophthalmol Scand 2006, 84:781-5.
15. Fahnehjelm KT, Törnquist AL, Winiarski J. Ocular axial length and corneal refraction in children with mucopolysaccaridosis (MPS I-Hurler): Acta Opthalmologica. 2010, doi: 10.1111/j.1755-3768.2010.01934.x
16. Karageorgos L, Brooks DA, Pollard A. Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 2007, 28:897-903.
17. Beesley CE, Meaney CA, Greenland G. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet 2001, 109:503-11.
18. Pastores GM, Arn P, Beck M. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol Genet Metab 2007, 91:37-47.
19. Azevedo ACMM, Schwartz IV, Kalakun L. Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI. Clin Genet 2004, 66:208-13.
20. Martins AM, Dualibi AP, Norato D. Guidelines for the management of mucopolysaccharidosis type I. J Pediatr 2009, 155:S32-S46.
21. Alroy J, Haskins M, Birk DE. Altered corneal stromal matrix organization is associated with mucopolysaccharidosis I, III and VI. Exp Eye Res 1999, 68:523-30.
22. Summers CG, Whitley CB, Holland EJ, Purple RL, Krivit W. Dense peripheral corneal clouding in Scheie syndrome. Cornea 1994, 13:277-9.
23. Cantor LB, Disseler JA, Wilson FM. Glaucoma in the Maroteaux-Lamy syndrome. Am J Ophthalmol 1989, 108:426-30.
24. Caruso RC, Kaiser-Kupfer MI, Muenzer J, Ludwig IH, Zasloff MA, Mercer PA. Electroretinographic findings in the mucopolysaccharidoses. Ophthalmology 1986, 93:1612-16.
25. Sato S, Maeda N, Watanabe H. Multiple iridociliary cysts in patients with mucopolysaccharidoses. Br J Ophthalmol 2002, 86:933-4.
26. Spellacy E, Bankes JLK, Crow J, Dourmashkin R, Shah D, Watts RWE. Glaucoma in a case of Hurler disease. Br J Ophthalmol 1980, 64:773-8.
27. Nowaczyk MJ, Clarke JTR, Morin JD. Glaucoma as an early complication of Hurler's disease. Arch Dis Child 1988, 63:1091-3.
28. Quigley HA, Maumenee AE, Stark WJ. Acute glaucoma in systemic mucopolysaccharidosis I-S. Am J Ophthalmol 1975, 80:70-2.
29. Mullaney P, Awad AH, Millar L. Glaucoma in mucopolysaccharidosis 1-H/S. J Pediatr Ophthalmol Strabismus 1996, 33:127-31.
30. Collins MLZ, Traboulsi EI, Maumenee IH. Optic nerve head swelling and optic atrophy in the systemic mucopolysaccharidoses. Ophthalmology 1990, 97:1445-9.
31. Schumacher RG, Brzezinska R, Schulze-Frenking G, Pitz S. Sonographic ocular findings in patients with mucopolysaccharidoses I, II and VI. Pediatr Radiol 2008, 38:543-50.
32. Pitz S, Ogun O, Bajbouj M, Arash L, Schulze-Frenking G, Beck M. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience. Arch Ophthalmol 2007, 125:1353-6.
33. Pitz S, Ogun O, Arash L, Miebach E, Beck M. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis? Graefes Arch Clin Exp Ophthalmol 2009, 247:975-80.
34. Yoon MK, Chen RW, Hedges TR. High-speed, ultrahigh resolution optical coherence tomography of the retina in Hunter syndrome. Ophthalmic Surg Lasers Imaging 2007, 38:423-8.
35. Tonnu PA, Ho T, Newson T. The influence of central corneal thickness and age on intraocular pressure measured by pneumotonometry, non-contact tonometry, the Tono-Pen XL, and Goldmann applanation tonometry. Br J Ophthalmol 2005, 89:851-4.
36. Grupcheva CN, Craig JP, McGhee CNJ. In vivo microstructural analysis of the cornea in Scheie's syndrome. Cornea 2003, 22:76-9.
37. Mocan MC, Eldem B, Irkec M. In vivo confocal microscopic findings of two siblings with Maroteaux-Lamy syndrome. Cornea 2007, 26:90-3.
38. Patel DV, Ku JYF, Kent-Smith B, McGhee CNJ. In vivo microstructural analysis of the cornea in Maroteaux-Lamy syndrome. Cornea 2005, 24:623-5.
39. Maskin SL, Heitman KF, Lawton AW, Yee RW. Diagnostic impression cytology for external eye disease. Cornea 1989, 8:270-3.
40. Riordan-Eva P, Whitcher JP. Basic ophthalmologic examination. Vaughan & Ashbury's General Ophthalmology 2004, 31-61. Riordan-Eva P, Whitcher JP. eds, eds, 16th, edn., New York, McGraw-Hill Medical Publishing Division
41. Kim SW, Byun YJ, Kim EK, Kim TI. Central corneal thickness measurements in unoperated eyes and eyes after PRK for myopia using Pentacam, Orbscan II, and ultrasonic pachymetry. J Refract Surg 2007, 23:888-94.
42. Francis BA, Hsieh A, Lai MY. Effects of corneal thickness, corneal curvature, and intraocular pressure level on Goldmann applanation tonometry and dynamic contour tonometry. Ophthalmology 2007, 114:20-6.
43. Hodd DC, Bach M, Brigell M. ISCEV Guidelines for Clinical Multifocal Electroretinography. http://www.iscev.org/standards/pdfs/mfERGSguidelines9-07r3.pdf, 2007 edition). Accessed April 2010. Available from:
44. Tzetzi D, Hamilton R, Robinson PH, Dutton GN. Negative ERGs in mucopolysaccharidoses (MPS) Hurler-Scheie (I-H/S) and Hurler (I-H)-syndromes. Doc Ophthalmol 2007, 114:153-8.
45. Ashworth J. Ocular changes and outcomes in MPS I. Curr Med Lit 2009, 1:6-11.
46. Odom JV, Bach M, Brigell M. ISCEV standard for clinical visual evoked potentials. Doc Ophthalmol 2010, 120:111-19.
47. Suppiej A. General characteristics of evoked potentials: retinal and cortical visual evoked potentials. Neonatal and Paediatric Neurophysiology 2007, 111-54. Pressler RBinnie CDCooper RRobinson R. In, eds., Edinburgh, Churchill Livingstone
48. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007, 120:405-18.